Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.

Patients with chronic kidney disease (CKD), hyperkalemia (serum potassium [sK A post hoc pooled analysis of individual-level data from the AMETHYST-DN, OPAL-HK, and TOURMALINE trials of patiromer. Patients with CKD and hyperkalemia. Patients treated with patiromer (8.4-33.6 g/day). Mean changes from baseline in sP, sK Descriptive statistics to summarize pooled data on the study outcomes from the 3 studies. We included 578 patients in the analysis. Of these participants, 86 patients (14.9%) had baseline hyperphosphatemia of whom 75.6% (65 of 86) had CKD stage 4/5 and 31.1% (153 of 492) with sP≤4.5mg/dL had CKD stage 4/5. Among the patients with elevated sP and sK These were post hoc analyses, no placebo comparison was performed due to the design of the original studies, and the follow-up period was limited to 4 weeks. Reductions in sP and sK

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.